Literature DB >> 8635860

Altered expression of CD44 isoforms in squamous-cell carcinomas and cell lines derived from them.

D L Hudson1, P M Speight, F M Watt.   

Abstract

CD44 is a transmembrane glycoprotein that binds hyaluronan, extracellular matrix proteins and growth factors. Multiple isoforms of CD44 are generated by alternative splicing of 10 separate exons (V1-V10). Expression of the variable exons has been correlated with tumour progression and metastasis in a range of cell types. However, multiple CD44 isoforms are expressed by normal stratified squamous epithelia, such as the epidermis and the lining of the oral cavity. The purpose of our study was to examine CD44 expression in squamous-cell carcinomas (SCC). By immunofluorescence we found reduced expression of one or more of the variant exons in a series of 13 oral SCC, with loss being most common in poorly differentiated tumours. Of the exons we examined, V3 was lost most frequently, but otherwise there was no consistent pattern as to which exons (V4/5, 6, 8) were missing. We also studied CD44 expression in a range of SCC lines, using Western blotting and semi-quantitative RT-PCR. All lines showed reduced expression of the terminal differentiation marker involucrin. Two lines showed selective loss of the largest forms of CD44 and one failed to express any of the variant exons. These cell lines, therefore, provide a useful experimental model with which to study the biological significance of exon loss in SCC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635860     DOI: 10.1002/(SICI)1097-0215(19960516)66:4<457::AID-IJC8>3.0.CO;2-V

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  Prostate epithelial stem cells.

Authors:  S Rizzo; G Attard; D L Hudson
Journal:  Cell Prolif       Date:  2005-12       Impact factor: 6.831

2.  Tumor-associated antigen expression and growth requirements predict tumorigenesis in squamous cell carcinoma.

Authors:  E R Salter; D Tichansky; E E Furth; A M Herlyn
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-09       Impact factor: 2.416

Review 3.  The normal structure and function of CD44 and its role in neoplasia.

Authors:  R J Sneath; D C Mangham
Journal:  Mol Pathol       Date:  1998-08

4.  Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44.

Authors:  Yuriko Kinugasa; Masashi Hatori; Hidetoshi Ito; Yuji Kurihara; Daisuke Ito; Masao Nagumo
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  Podoplanin associates with CD44 to promote directional cell migration.

Authors:  Ester Martín-Villar; Beatriz Fernández-Muñoz; Maddy Parsons; Maria M Yurrita; Diego Megías; Eduardo Pérez-Gómez; Gareth E Jones; Miguel Quintanilla
Journal:  Mol Biol Cell       Date:  2010-10-20       Impact factor: 4.138

6.  CD44 expression in oro-pharyngeal carcinoma tissues and cell lines.

Authors:  Abirami Rajarajan; Angela Stokes; Balvinder K Bloor; Rebecca Ceder; Hemini Desai; Roland C Grafström; Edward W Odell
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

7.  The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas.

Authors:  S Maula; R L Huuhtanen; C P Blomqvist; T A Wiklund; P Laurila; R Ristamäki
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

8.  Immunohistochemical study of CD44s expression in oral squamous cell carcinoma-its correlation with prognostic parameters.

Authors:  Kn Hema; Kavita Rao; Hs Uma Devi; Ns Priya; T Smitha; Hs Sheethal
Journal:  J Oral Maxillofac Pathol       Date:  2014-05

9.  FRMD4A upregulation in human squamous cell carcinoma promotes tumor growth and metastasis and is associated with poor prognosis.

Authors:  Stephen J Goldie; Klaas W Mulder; David Wei-Min Tan; Scott K Lyons; Andrew H Sims; Fiona M Watt
Journal:  Cancer Res       Date:  2012-05-07       Impact factor: 12.701

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.